Medicaid coverage of weight-loss drugs could cost state up to $70M a year
The planned new rule, announced by the White House in November, would greatly expand Medicare Part D and Medicaid coverage for popular medications such as Eli Lilly and Co.’s Zepbound and Novo Nordisk’s Ozempic and Wegovy to treat obesity alone.... Read More